Comparing the current results to its competitors, Shuttle Pharmaceuticals Holdings Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 46.47 %, recorded in the same quarter.
Shuttle Pharmaceuticals Holdings Inc 's Comment on Competition and Industry Peers
Molecule.ai is developing its molecule predictive capabilities and automated multi-tool workflows to advance agentic AI systems and integrated end-to-end platforms in AI-driven drug discovery. The company has introduced a new module designed to evaluate the likelihood of chemical–protein interactions, assisting researchers in estimating molecule interactions with biological targets.
December 19, 2024
Shuttle Pharmaceuticals: A New Alliance in Cancer Research Amidst Market Challenges In a significant development for both Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) and the broader field of oncology, the company recently announced a sponsored research agreement with the University of California, San Francisco (UCSF) to advance its prostate-specific membrane antigen (PSMA) development program. This collaboration aims to further the pre-clinical development of Shuttle Diagnostics, Inc. s ligand targeting PSMA, which holds promise as a dual-purpose diagnostic and therapeutic agent also referred to as a theranostic molecule. As the company s research initiatives gain momentum, the broader financial la...
September 16, 2024
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma GAITHERSBURG, Md. Sept. 16, 2024 Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a pioneering specialty pharmaceutical company operational in the discovery and development stage, has announced significant advancements in its clinical trial for Ropidoxuridine, a promising treatment for patients battling glioblastoma. This latest development highlights Shuttle Pharma s commitment to improving treatment outcomes for cancer patients undergoing radiation therapy (RT).In an effort to expedite patient enrollment and broaden the footprint of its Phase 2 clinical trial, Shuttle Ph...
Publicly Traded Peers of Shuttle Pharmaceuticals Holdings Inc
Zymeworks Inc Share Performance
+13.07%
This Quarter
Zymeworks Inc
Profile
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Shuttle Pharmaceuticals Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Shuttle Pharmaceuticals Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
